You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.
I was reminded recently of why I dig mass transit upon overhearing the train conductor and two middle-aged men engaged in a serious talk about mattresses, “trash” 400-thread-counts, and the pros and cons of weighted sheets. Send me your suggestions for a luxurious night’s sleep, and news tips to [email protected] or John_Wilkerson.07 on Signal.
It’s who you know that matters
Sarepta Therapeutics, which has come under regulatory pressure over its gene therapy for Duchenne muscular dystrophy, hired the Trump-connected lobbying firm Michael Best Strategies after the death of a teenage boy treated with the drug, according to lobbying disclosure reports.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
